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Protecting against both liver and blood stages of
infection is a long-sought goal of malaria vaccine
design. Recently, we described the use of replica-
tion-defective viral vaccine vectors expressing the
malaria antigen merozoite surface protein-1 (MSP-1)
as an antimalarial vaccine strategy that elicits potent
and protective antibody responses against blood-
stage parasites. Here, we show that vaccine-induced
MSP-1-specific CD4+ T cells provide essential help
for protective B cell responses, and CD8+ T cells
mediate significant antiparasitic activity against
liver-stage parasites. Enhanced survival is subse-
quently seen in immunized mice following challenge
with sporozoites, which mimics the natural route of
infection more closely than when using infected red
blood cells. This effect is evident both in the pres-
ence and absence of protective antibodies and is
associated with decreased parasite burden in the
liver followed by enhanced induction of the cytokine
IFN-g in the serum. Multistage immunity against
malaria can thus be achieved by using viral vectors
recombinant for MSP-1.
INTRODUCTION
Approximately 500 million cases and 1 million deaths occur
annually due to Plasmodium falciparummalaria infection (Green-
wood et al., 2008). The development of an effective vaccine
remains an important goal for the safe and cost-effective control
of this disease. Blood-stage malaria vaccine development has
classically focused on recombinant protein-in-adjuvant formula-
tions (Genton and Reed, 2007); however, we have described the
use of replication-defective viral vaccine vectors expressing the
malaria antigen merozoite surface protein-1 (MSP-1) as a prom-
ising alternative vaccination strategy (Draper et al., 2008).
MSP-1 is a large polypeptide that undergoes proteolytic pro-
cessing upon erythrocyte invasion, during which the 42 kDa
C terminus (MSP-142) is cleaved into 33 kDa (MSP-133) and
19 kDa (MSP-119) fragments (Holder et al., 1987). High-titer anti-
body responses against MSP-119, but not MSP-133, are reportedCellto account for the protective immunity induced by this antigen
(Ahlborg et al., 2002; Yuen et al., 2007). Previously, we have
demonstrated that a priming immunization with adenovirus
human serotype 5 (AdHu5) followed by a boost with modified
vaccinia virus Ankara (MVA), both recombinant for P. yoelii
MSP-142, can induce potent antibody responses that protect
against a lethal challenge with blood-stage parasites.
Viral vaccine vectors, deployed in heterologous prime-boost
regimes, have been routinely developed to induce strong T cell
responses targeting intracellular pathogens (Hill, 2006), and as
expected, the AdHu5-MVA-MSP-1 regime also induced potent
MSP-1-specific T cell responses in mice (Draper et al., 2008).
However, we demonstrated that depletion of T cell responses
in mice prior to blood-stage challenge did not ablate vaccine
efficacy, despite the fact that CD4+ T cell lines that recognize
epitopes within MSP-133 are reported to control the growth
of P. yoelii following adoptive transfer into immunodeficient
mice (Wipasa et al., 2002). Nevertheless, MSP-1 is reported to
be expressed within the exoerythrocytic schizonts (Sacci et al.,
2005), and T cells against P. yoelii MSP-1 have been reported
to protect against the liver-stage parasite using a heat shock
protein fusion construct (Kawabata et al., 2002). We therefore
sought to investigate whether the induction of cellular immune
responses, in conjunction with antibody responses, could
enhance vaccine efficacy by targeting the parasite at both the
liver and blood stages of malaria infection.
Here, we describe in detail the immunemechanisms elicited in
mice immunized with AdHu5-MVA-MSP-1 vaccines. We show
that CD4+ T cell responses against MSP-133 provide essential
help for priming B cell responses against MSP-119, while CD8
+
T cell responses against MSP-133 mediate significant anti-
parasitic activity against the liver stage. In agreement with pro-
tein vaccine studies (Ahlborg et al., 2002), MSP-133-specific
responses alonedonotmediate blood-stageprotection following
challenge infection with parasitized red blood cells (pRBCs).
However, the AdHu5-MVA-MSP-1 vaccine regimes demonstrate
consistently better protection against a lethal blood-stage infec-
tion following challenge with P. yoelii sporozoites, rather than
inoculation with pRBCs. Enhanced efficacy following sporozoite
(spz) challenge is associated with vaccine-induced effector
mechanismsactingagainst the liverandbloodstagesof infection.
Thesedatademonstrate thatmultistage immunity againstmalaria
canbeachievedusinga single vaccineplatform that inducesboth
strong antibody and T cell responses against theMSP-1 antigen.Host & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc. 95
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Immunogenicity of AdHu5-MVA-MSP-1 Recombinants
The immunogenicity of heterologous prime-boost immunization
using AdHu5 and MVA vectors expressing MSP-142 has been
previously reported (Draper et al., 2008), however, we sought
to address the contribution of theMSP-133 andMSP-119 compo-
nent domains of MSP-142 to immunogenicity.
Mice were immunized as described in Figure 1 using AdHu5-
MVA vectors expressing the MSP-142, MSP-133, or MSP-119
antigen (AdM42, AdM33, or AdM19, respectively), and antigen-
specific immune responses were assayed. Relatively weak
CD4+ T cell responses could be detected in the spleens of
AdM42- and AdM33-immunized mice by intracellular cytokine
staining (ICS) using a pool of overlapping peptides to MSP-133
(Figure 1A). These CD4+ T cells almost exclusively produced
only IFN-g. In contrast, multifunctional CD8+ T cell responses
toMSP-133 were detected. These populations of T cells secreted
various combinations of IFN-g, TNF-a, and IL-2 and were of
similar magnitude in mice immunized with AdM42 and AdM33
(Figure 1B). A clear hierarchy was also evident with a dominant
population composed of IFN-g+ TNF-a+ ‘‘double-positive’’ cells,
followed by a population that produced only IFN-g, and finally, a
small population that was ‘‘triple-positive’’ and secreted all three
cytokines, indicating only low-level production of IL-2 in compar-
ison to IFN-g and TNF-a. No regime induced MSP-119-specific
T cell responses that could be detected by ICS (data not shown).
As previously reported, mice immunized with the AdM42 regime
developed strong total IgG responses against the entire antigen,
while in comparison, mice immunized with AdM33 developed
a significantly higher total IgG response against MSP-133 (Fig-
ure 1C). Interestingly, in contrast to mice immunized with
AdM42, those immunized with AdM19 developed no detectable
antibody response to MSP-119 (Figure 1C). However, antibody
responses in mice that were primed with Ad42 could be boosted
by MVA expressing MSP-119 (Ad42M19 regime; Figure 1D).
These data indicate that essential T cell help for priming naive
B cell responses against MSP-119 comes from T cells induced
against MSP-133, but that there exists a different, and possibly
reduced, requirement for CD4+ T cell help for memory B cells
activated by a secondary exposure to the MSP-119 antigen.
Efficacy of AdHu5-MVA Recombinants
against pRBC Challenge
We have reported that AdM42 immunization can protect 76%
of BALB/c mice (13 of 17) against a lethal challenge with 104
P. yoelii pRBCs (Draper et al., 2008). That study did not confirm
whether antibodies againstMSP-133 played a role in blood-stage
immunity. Here, we assessed the protective efficacy of AdM33
and AdM19 immunization against a blood-stage challenge (Fig-
ure 2A). None of the mice immunized with AdM33 survived
challenge, despite higher total IgG responses and similar T cell
responses against MSP-133 as compared to mice immunized
with AdM42 (Figure 1). This confirms that no protection is medi-
ated in this pRBC challenge model by MSP-133-specific immune
responses alone. Survival was seen in four of six mice (67%)
immunized with Ad42M19, and notably, these mice possessed
only high-titer IgG responses toMSP-119 (Figure 1D). In contrast,
none of the mice immunized with AdM19 was protected, which96 Cell Host & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevierwas unsurprising, given the absence of detectable immune
responses induced by this vaccine regime (Figure 1). In agree-
ment with our previous report, protection in this pRBC challenge
model is dependent on MSP-119-specific IgG.
Efficacy of AdHu5-MVA Recombinants against
Sporozoite Challenge
Malaria challenge with pRBCs does not mimic the natural mode
of malaria infection by sporozoites. The efficacy of AdHu5-
MVA-MSP-1 immunization against spz challenge was thus
investigated (Figure 2B). After a lag period corresponding to the
pre-erythrocytic infection, naive control mice succumbed to
infection in an identical manner to those challenged with pRBCs
and with near-identical parasitemia profiles (Figure S2A), sug-
gesting that parasite virulence between the two challenge
models is comparable. Nevertheless, all of the mice immunized
with AdM42 developed patent blood-stage parasitemia (Fig-
ure S2B) but were able to control blood-stage parasite growth
and clear the infection (Figure 2B). Indeed, following spz rather
than pRBC challenge, blood-stage protection (using percent
survival as the outcomemeasure) showed a significant increase,
from 76% (Draper et al., 2008) to 100%, in mice immunized with
AdM42, p = 0.046. Survival was also enhanced by a similar
margin, to 25%, in mice immunized with AdM33 following spz
challenge (Figures 2B and S2A), as compared to 0% in naive
controls following spz challenge (p = 0.044) or 0% in mice immu-
nized with AdM33 following pRBC challenge (Figure 2A). None of
the mice immunized with AdM19 survived spz challenge.
We postulated that a number of factors could potentially
contribute to an increase in vaccine efficacy following spz
rather than pRBC challenge. These factors, in concert with
MSP-119-specific IgG, may enhance blood-stage protection
mediated by AdM42 immunization, or in a small number of
cases, lead to survival against blood-stage infection in mice
immunized with AdM33 that lack protective antibodies. Indeed,
we had consistently noted a significant reduction in blood-stage
parasitemia in mice immunized with AdM33 on day 5 after spz
challenge (48 hr after merozoite release from the liver), but
not 48 hr after direct blood-stage infection by pRBC challenge
(Figure 2C). We therefore sought to investigate a possible anti-
parasitic effect induced by AdM42 and AdM33 immunization
against the liver-stage parasite.
MSP-133-Specific CD8
+ T Cell Responses Mediate
Partial Efficacy against the Liver-Stage Parasite
The exoerythrocytic cycle of P. yoelii lasts approximately 50 hr
(Killick-Kendrick and Peters, 1978). Given that AdM42 and
AdM33 immunization elicits strong CD8+ T cell responses
against MSP-133 (Figure 1B), it is possible that these effector
T cells can protect against the late exoerythrocytic schizonts
that contain merozoites expressing MSP-1. To address this
question, mice were immunized with AdM42 or with the previ-
ously described vaccines expressing MSP-142 fused to mouse
complement C4b-binding protein (C4bp) (Draper et al., 2008)
and were challenged with 5000 sporozoites, and the liver-stage
parasite burden was quantified using a real-time RT-PCR assay
(Figure 3A). Mice immunized with both regimes showed a signif-
icant reduction in comparison to naive controls. These data are
in agreement with challenge studies using 50 sporozoites,Inc.
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Figure 1. Immunogenicity of AdHu5-MVA-MSP-1 Recombinants
(A and B) BALB/c mice were primed i.d. with AdHu5 expressingMSP-142, MSP-133, or MSP-119 (Ad42, Ad33, or Ad19 respectively) and boosted i.d. 56 days later
with the corresponding MVA vector (M42, M33, or M19). Fourteen days after boost, splenocytes were restimulated with MSP-133 peptides, and the production of
IFN-g, TNF-a, and IL-2 byCD4+ (A) andCD8+ (B) T cells in the spleenwas assessed using polychromatic flow cytometry. The functional compositions of theCD4+
and CD8+ T cell responses are shown, and these are grouped and color-coded according to the vaccine regime and number of cytokines secreted by each T cell
population. The pie charts in (B) summarize the fractions of MSP-133-specific CD8
+ T cells that are positive for a given number of functions. Individual data points
and mean percentage of the total response (open bars) are shown for each of the functional populations indicated on the x axis. No responses were detected
above background following restimulation with MSP-119 peptides (data not shown). Representative flow cytometry plots and the gating strategy are shown in
Figure S1.
(C and D) Total IgG serum antibody responses against MSP-119 and MSP-133 were measured by ELISA in mice primed and boosted as indicated. Mean
responses ± SEM are shown (n = six mice per group). N.D. = not detected. * p% 0.05 in (C) (independent Student’s t test comparing responses between the
AdM42 and AdM33 groups). Similar results were obtained in three independent experiments.whereby the observed partial reduction in liver-stage parasite
burden would not result in sterile immunity and hence not
prevent blood-stage infection (Figures S2B and S2C). To confirm
the role of T cells in mediating liver-stage immunity, mice were
immunized with AdM42-C4bp and then depleted of T cells prior
to spz challenge. Depletion of CD8+ T cells and, to a lesser
extent, CD4+ T cells attenuated the vaccine-induced reduction
in liver-stage parasite burden (Figure 3B).
Given that the CD8+ T cell response elicited by the AdM42
vaccine regime in BALB/c mice is targeted against epitopes
within MSP-133 (Sridhar et al., 2008), and given that the AdM33
regime described here induces a similar T cell response to
AdM42 (Figure 1), we sought to confirm that this vaccine could
mediate similar efficacy against the liver-stage forms of P. yoelii.
BALB/c mice were immunized with AdM33 or vector controls
(AdM-GFP). A significant reduction in liver-stage parasite burdenCellwas observed with AdM33 (Figure 3C), similar to that previously
seen with AdM42. The reduced liver-stage burden with AdM33
was reflected in the levels of blood-stage parasitemia on day 5
following challenge with 50 sporozoites (Figure 3D). In vivo
depletion of the CD8+ and CD4+ T cell subsets again confirmed
that this protective effect is primarily dependent on CD8+ and not
on CD4+ T cells, as noted by a loss of this reduction in blood-
stage parasitemia on day 5 (Figure 3E). Partial efficacy against
the liver-stage parasite in this model can thus be attributed to
the T cell response against the MSP-133 antigen when used
alone or in the context of MSP-142.
Viral Vector Immunization Mediates Short-Term
Efficacy against Sporozoite Challenge
During these spz challenge experiments (conducted 14 days
after boosting), we noted a small and consistent but notHost & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc. 97
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day 5 postchallenge in mice immunized with AdM19 and AdM-
GFP (Figure 3D). This effectwas not apparent following challenge
at a later time point (data not shown). It has been reported that
potent Th1-type innate immune responses induced by CpG
immunization canmediate short-term protection against P. yoelii
spz challenge, which is dependent on IFN-g and IL-12 and, in
some cases, also NK cells, nitric oxide, and CD8+ T cells (Gram-
zinski et al., 2001). We tested the possibility that this may also be
the case for viral vectored vaccines, whereby short-term protec-
tion can be mediated against spz challenge by vector control
vaccines. Mice were primed with Ad-GFP and boosted with
MVA-GFP 8 weeks later or simply primed with MVA-GFP alone.
Mice were then challenged 2, 4, or 14 days later with 50 sporozo-
ites. Eighty-threepercent of themicechallengedonday2orday4
were protected against challenge and did not develop blood-
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Figure 2. Survival against pRBC and Sporo-
zoite Challenge
(A–C) BALB/c mice were immunized as indicated.
Fourteen days after the final immunization, these
mice or naive controls were challenged i.v. with
104 pRBCs (A) or 50 sporozoites (B), and Kaplan-
Meier plots show survival over time. Data were
pooled frommultiple experiments, and the number
of mice challenged in total (n) is indicated for each
group. As shown in (C), mice immunized with
AdM33 or naive controls were challenged with
104 pRBCs or 50 sporozoites. Parasitemia in the
blood was measured postchallenge by micros-
copy. Plots show the mean parasitemia ± SEM
(n = sixmice per group) for the first 4 days following
patency. * p% 0.05, ** p% 0.01, and *** p% 0.001
(independent Student’s t test comparing percent
parasitemia at each time point between the
immunized and naive control mice).
stage parasitemia (Table 1). This protec-
tive effect was the same following either
a single immunization with MVA-GFP
or AdM-GFP prime-boost, indicating
a strong immune response against the
MVA vector, rather than a strong boosting
of the immune response against that of
the GFP transgene, is accounting for
protection (immune responses against
GFP have been documented in BALB/c
mice [Gambotto et al., 2000]). In vivo
depletion studies suggested this protec-
tive effect is mediated by CD8+ and
CD4+ T cells and NK cells, but not by
macrophages (Table 1).
AdM42 ImmunizationProtectsMice
against a High-Dose Sporozoite
Challenge
Having established that AdM42 and
AdM33 immunization can mediate an
antiparasitic effect at the liver stage, we
sought to assess whether the increased
survival outcome against spz challenge
was due to a reduction in the blood-stage inoculum from the
liver. A single hepatic schizont of P. yoelii malaria will produce
approximately 7500–8000 merozoites (Killick-Kendrick and
Peters, 1978). Consequently, just two infected hepatocytes
should release a larger blood-stage inoculum than the 104
pRBCs used in the blood-stage challenge model. Levels of
blood-stage parasitemia were compared 2 days post blood-
stage infection in naive BALB/c mice challenged with 104
pRBCs, 50 sporozoites (low dose), or 250 sporozoites (high
dose) (Figure 4A). These data showed that spz challenge in
naive mice leads to a significantly higher blood-stage parasite-
mia after 48 hr of blood-stage infection when compared to
pRBC challenge. Mice immunized with AdM33 have a reduced
liver-stage parasite burden (Figure 3C) but do not possess
protective IgG. The same assessment of blood-stage parasite-
mia in mice immunized with AdM33 and challenged with 50
98 Cell Host & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc.
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Figure 3. AdHu5-MVA-MSP-1 Immunization Efficacy against Liver-Stage Infection
(A–E) BALB/c mice were immunized with AdM42 or AdM42-C4bp (A), AdM42-C4bp (B), or AdM33 or AdM-GFP vector controls (C), and challenged with 5000
sporozoites 14 days after the boost. Liver-stage parasite burden was quantified 48 hr postchallenge using an established real-time RT-PCR assay (Bruna-
Romero et al., 2001). In (B), mice immunized with AdM42-C4bp were depleted of CD8+ or CD4+ T cells or control depleted with normal rat IgG (nRat IgG) prior
to challenge. (D) shows blood-stage parasitemia on day 5 in BALB/c mice immunized as indicated or immunized with AdM33 and depleted of T cell subsets as
indicated (E) and challenged with 50 sporozoites. The mean ratio or parasitemia ± SEM is shown (n = five or six mice per group). * p% 0.05 and ** p% 0.01,
comparing between all groups by one-way ANOVA.sporozoites showed, interestingly, that the mean parasitemia
level was significantly reduced to one comparable with pRBC
challenge (Figure 4A). These data indicate that if the amount
of blood-stage inoculum from the liver was the sole determi-
nant of survival outcome, then mice immunized with AdM33
and challenged with 104 pRBCs or 50 sporozoites should
show the same percent survival outcome, which was not the
case (Figures 2A and 2B).CellVaccines developed against P. yoelii can show reduced
efficacy against a high-dose challenge with 250 sporozoites (Se-
degah et al., 2002). To confirm that protective efficacy wasmain-
tained at a higher blood-stage inoculum, mice were immunized
with AdM42 and challenged with 250 sporozoites. All of the
immunized mice (12 of 12) survived this higher dose challenge,
compared to 0 of 8 naive control mice. Complete survival is
thus maintained even after a high-dose P. yoelii spz challenge.Host & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc. 99
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Immunization Regime Day Challenged Treatment No. Infected / Total % Protection P value
AdM-GFP +2 N/A 1/6 83% 0.015
AdM-GFP +4 N/A 1/6 83% 0.015
M-GFP +4 N/A 1/6 83% 0.015
AdM-GFP +14 N/A 6/6 0%
Naive N/A N/A 6/6 0%
AdM-GFP +2 Control IgG 1/6 83%
AdM-GFP +2 Anti-CD8+ T cells 3/4 25% 0.19
AdM-GFP +2 Anti-CD4+ T cells 3/4 25% 0.19
AdM-GFP +2 Anti-Macrophages 1/4 75%
AdM-GFP +2 Anti-NK cells 3/4 25% 0.19
Naive N/A Control IgG 4/4 0%
Naive N/A Anti-Macrophages 4/4 0%
Mice were immunized with AdHu5-MVA prime-boost or MVA alone expressing GFP and challenged with 50 sporozoites 2, 4, or 14 days after the MVA
immunization. Mice were depleted as described in Experimental Procedures. P values were calculated using Fisher’s exact test (two-tailed) by
comparing protection in immunized mice versus naive controls or protection in mice receiving treatment versus controls.An Effective T Cell Response against the Liver-Stage
Parasite Does Not Lead to Defective Growth
of Blood-Stage Parasites
An alternative explanation for these survival data could be defec-
tive blood-stage growth by parasites that were damaged by
antigen- or vector-specific immune mechanisms in the liver.
However, AdHu5 vaccines encoding the P. yoelii circumsporo-
zoite protein (PyCSP) have been reported to induce highly
protective CD8+ T cell responses against spz challenge (Ro-
drigues et al., 1997) but not to affect subsequent blood-stage
survival. To confirm that parasites do not have defective
blood-stage growth following an effective liver-stage immune
response, mice were immunized with AdM33 or given a single
immunization of 1 3 108 viral particles (vp) AdHu5-PyCSP and
then challengedwith 50 sporozoites. This dose of AdHu5-PyCSP
vaccine was titered to give a similar reduction in liver-stage
parasite burden as AdM33 but not sterilizing immunity. Mean
blood-stage parasitemias, as measured on day 5 postinfection,
were comparable between the immunized groups, and both
were significantly lower than naive controls (Figure 4B).
However, in the case of the AdHu5-PyCSP vaccine, none of
the mice survived blood-stage infection (Figure 2B). These
data indicate that P. yoelii parasites released into the blood are
viable despite a partially effective response at the liver-stage.
Priming a CD4+ T Cell Response against MSP-133 Leads
to the Faster Induction of De Novo Antibody Responses
against MSP-119
We hypothesized that an alternative explanation for the
observed increase in survival may be due to an enhanced de
novo production of protective anti-MSP-119 IgG responses in
mice previously immunized with AdM33. In this scenario, CD4+
T cell helper responses would be primed and ready to assist
naive B cells immediately upon natural exposure to MSP-119
antigen. Serum antibody responses were measured in all mice
prechallenge and 120 hr post blood-stage infection. Indeed,
following spz challenge, 7 of 12 of the mice immunized with
AdM33 had developed detectable IgG responses against100 Cell Host & Microbe 5, 95–105, January 22, 2009 ª2009 ElsevieMSP-119 within 5 days (Figure S3). Only two other mice within
all of the other vaccinated or control groups possessed a detect-
able IgG antibody response against this domain. However, the
levels of these detected antibodies were far below the protective
threshold established in previous work (Draper et al., 2008), and
furthermore, a similar number (5 of 11) of mice immunized with
AdM33 and challenged with pRBCs also developed detectable
MSP-119 IgG responses, but did not survive. So these weak anti-
body responses by themselves are highly unlikely to account for
protective efficacy at this time point.
Viral-Vector Immunization Enhances the IFN-g Serum
Cytokine Response against Blood-Stage Parasites
Following Sporozoite but Not pRBC Challenge
A balanced cytokine response is reported to be essential for the
control of blood-stage parasite growth. The ratio of protective
proinflammatory cytokines (such as IFN-g and TNF-a) to regula-
tory cytokines (such as IL-10 and TGF-b), has been shown to
determine the outcome of natural blood-stage infection with
lethal versus nonlethal P. yoelii (Omer et al., 2003) and to corre-
late with the growth rate of blood-stage parasites in malaria-
naive human volunteers (Walther et al., 2006). We hypothesized
that exposure of vaccine-induced T cells to MSP-1 at the liver
stage (after spz challenge) might allow for the development of
a qualitatively or quantitatively different and more protective
cytokine response than is developed in mice challenged only
with pRBCs, who will not have had this antecedent activation
of T cells prior to blood-stage infection. Mice were thus immu-
nized and then challenged with pRBCs or sporozoites. Blood
samples were taken prechallenge and 2 days and 5 days after
the onset of blood-stage infection, and serum cytokines were
assessed using a cytometric bead array assay. Mice that were
immunized with AdM33 and not challenged (‘‘AdM33 control’’)
showed no detectable serum cytokine responses at any time
point (Figures 5A, 5C, and 5E). Naive mice challenged with
pRBCs or sporozoites showed a similar induction of IFN-g,
TNF-a, and IL-10 in the serum by 120 hr post blood-stage
infection (Figures 5A–5F). Yet mice that were immunized withr Inc.
Cell Host & Microbe
Viral Vaccines Induce Multistage Malaria ImmunityAdM33 and then challenged with pRBCs showed a significant
early induction of IFN-g after 48 hr, which was then significantly
downregulated by 120 hr, when compared to naive controls
(Figure 5A). The level of IL-10 in the serum mirrored this trend
at the 120 hr time point in immunized mice and was significantly
lower than in the naive controls (Figure 5C). However, this was
not the case in mice immunized with AdM33 and challenged
with sporozoites. Their mean serum levels of IFN-g and IL-10
were similar to naive controls after 48 hr (Figures 5B and 5D),
and IFN-g was not downregulated by 120 hr (as it was for
pRBC-challenged mice) but was in fact significantly higher
(Figure 5B). In the case of mice immunized with AdM19, AdM-
GFP, or Ad-PyCSP, a similar trend was maintained, but none
of these groups possessed significantly higher levels of IFN-g
in the serum as compared to naive controls at this time point
(Figures 5B and S4). Serum levels of TNF-a were similar in all
the challenge groups (Figures 5E and 5F). These data indicate
that the increased survival in mice immunized with AdM33 and
then challenged with spz rather than pRBCs is associated with
a more effective and maintained induction of IFN-g—a pattern
similar to that seen in the nonlethal 17XNL strain of P. yoelii
and contrasting with the lethal 17XL parasite strain (Omer
et al., 2003).
DISCUSSION
Wereport a vaccination strategy that can induceprotectivemulti-
stage immunity against malaria by using viral vectors that are
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Figure 4. Blood-Stage Parasitemias in
Naive and Immunized Mice 48 hr after
Blood-Stage Infection
(A) BALB/c mice immunized with AdM33
were challenged with 50 sporozoites (n = 18), or
naive controls were challenged with 104 pRBCs
(n = 29), 50 sporozoites (n = 44), or 250 sporozoites
(n = 8). Blood-stage parasitemia 48 hr post
blood-stage infection was assessed by micros-
copy (day 5 post spz challenge and day 2 post
pRBC challenge). Data were pooled from multiple
experiments. Plots show median values, 25th–
75th percentiles, and range. One mouse in the
AdM33 group had 0% parasitemia on day 5.
(B) BALB/c mice were immunized with AdM33 or
1 3 108 vp AdHu5-PyCSP and challenged with 50
sporozoites 14 days later. The mean parasitemia ±
SEM is shown (n = five or six mice per group).
*p% 0.05 and *** p% 0.001, comparing between
all groups by one-way ANOVA.
suitable for human use (Catanzaro et al.,
2006; Hill, 2006). These viral vaccines ex-
pressing MSP-142, like protein vaccines,
allow for the induction of highly protective
IgG against MSP-119, which accounts
for the major protective mechanism in
this model against the blood-stage para-
site. However, unlike protein vaccines,
the concomitant induction of MSP-133-
specific T cells and, to a lesser extent,
antigen-nonspecific vector-induced responses can provide
partial liver-stage efficacy in this mouse model and should allow
for combination with similar partially effective pre-erythrocytic
antigen vectors (Hill, 2006). Following spz challenge of immu-
nized mice, the significantly reduced blood-stage inoculum is
associated with a maintained induction of IFN-g in the blood.
This in turn correlates with increased survival in mice immunized
against MSP-133 or complete survival in mice immunized with
MSP-142 (and which also possess protective IgG against
MSP-119). These data have important implications for the choice
of clinical challenge model used to assess new candidate blood-
stage malaria vaccines and demonstrate that the induction of
effective immune responses against both the liver and blood
stagesofmalaria infection can lead to increased vaccineefficacy.
The need for CD4+ T helper cell responses against MSP-133 to
prime antibody responses against MSP-119 is in agreement with
studies that show MSP-119 is refractory to antigen processing
(Hensmann et al., 2004). Similarly, following immunization of
naive humans with an MSP-142 formulation in a phase I clinical
trial, T cell responses were identified against MSP-133 and not
MSP-119 (Huaman et al., 2008). The ability of the vectors ex-
pressing MSP-119 to boost but not prime these antibody
responses would support the use of MSP-119 recombinant
protein vaccines to boost antibody responses primed by viral
vectors expressing MSP-142.
CD8+ T cell responses were detected only against MSP-133,
and their ability to mediate liver-stage protection is consistent
with the expression of MSP-1 during liver-stage infection (Sacci
Cell Host & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc. 101
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comparable liver-stage efficacy (Kawabata et al., 2002) using
a T cell-inducing vaccine technology that required intravenous
vaccine administration. The inability of MSP-133-specific
T cells and IgG to protect against a pRBC challenge is in agree-
ment with some (Ahlborg et al., 2002) but not all (Wipasa et al.,
2002) previous studies. Taken together, these data argue for
the use of MSP-142- rather than MSP-119-based vaccines to
increase the likelihood of inducing multistage protection.
Antimalarial factors that can reduce liver-stage burden,
including bednets (Lengeler, 2004), immunogenetic risk factors
(Hill et al., 1991), and the RTS,S/AS02 vaccine (Alonso et al.,
2004), can ameliorate the severity of subsequent blood-stage
infection in naturally exposed individuals. However, this effect
has not been reported in the literature for preclinical studies
of pre-erythrocytic-stage vaccine candidates. In our report,
enhanced survival following spz challenge appears to be due to
vaccine-induced effector mechanisms acting against both the
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Figure 5. Serum Cytokine Responses
Following pRBC and Sporozoite Challenge
(A–F) BALB/c mice were immunized as indicated
and challenged with 104 pRBCs (A, C, and E) or
50 sporozoites (B, D, and F) or not challenged
(‘‘AdM33 control’’) (A, C, and E). Serum was
collected prechallenge (0 hr), 48 hr post blood-
stage infection (day 5 post spz challenge and
day 2 post pRBC challenge), and 120 hr post
blood-stage infection (day 8 post spz challenge
and day 5 post pRBC challenge). Serum cytokine
levels were assayed by flow cytometry using a cy-
tometric bead array assay. Mean levels ± SEM are
shown (n = five or six mice per group) for IFN-g
(A and B), IL-10 (C and D), and TNF-a (E and F).
* p% 0.05, comparing between groups (indepen-
dent Student’s t test in [A] and [C]), and one-way
ANOVA in (B). Similar results were obtained in
two independent experiments.
liver and blood stages of infection. Immu-
nization with AdM42 or AdM33 leads to a
reduced merozoite load emerging from
the liver, which is then associated with
a more effective induction of protective
IFN-g early after blood-stage infection.
This is in comparison to pRBC challenge
where this cytokine appears to be
induced faster but then downregulated.
Although blood-stage parasites have
been reported to modulate immune cell
function (Urban et al., 1999; Wipasa
et al., 2001;Wykes et al., 2005), why cyto-
kine induction should be different
following inoculation of the blood via
sporozoites or pRBCs remains unknown.
In one study using P. chabaudi
parasites, differences in the cytokine
responses of CD4+ T cells were noted
after the infection of naive mice with
pRBCs versus mosquito bite (Fonseca
et al., 2007). In this model, Th1 cytokine responses were in fact
reduced following infection by the route of natural transmission.
In our model, however, antigen-specific responses have been
primed by vaccination, and so temporal activation of MSP-
1-specific T cell populations, innate effector cell types, or
antigen-presenting cells in the liver prior to blood-stage infection
may be an important factor in determining outcome. It should be
noted that this effect occurred significantly only in mice immu-
nized with AdM33, and not those immunized with Ad-PyCSP.
The activation of antigen-specific T cells during liver infection
may only influence the blood-stage infection if antigen expres-
sion is maintained by the parasite in the blood stage, explaining
why significantly increased serum levels of IFN-g were found in
mice immunized against MSP-1 but not CSP. Our data did not
indicate that, following a partially effective T cell response in the
liver, the remaining parasites were damaged or less virulent in
the blood stage. Similarly, an earlier induction of protective anti-
body responses against MSP-119 did occur in mice possessing
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these were not universal and could not alone count for the differ-
ences in survival observed between the two challenge models.
The assessment of blood-stage malaria vaccine efficacy in
phase I/IIa clinical trials can use one of two models. The spz
clinical challenge model allows for an assessment of complete
or partial protection at the liver stage in immunized volunteers,
and although blood-film positivity requires drug cure, partial
blood-stage efficacy can be observed prior to this in partially pro-
tectedvolunteersbyusing real-timePCR (Thompsonet al., 2008).
An alternative blood-stage parasite clinical challengemodel uses
a smaller blood-stage inoculum (compared to spz challenge),
which leads to a longer prepatent period and more time for
assessment of blood-stage parasite growth rates by real-time
PCR (Sanderson et al., 2008) but to date has only been utilized
in three clinical studies (Lawrence et al., 2000; Pombo et al.,
2002; Sanderson et al., 2008). With many promising new blood-
stage vaccine candidates entering the clinical phase, careful
consideration needs to be given to the choice of challengemodel
employed to assess efficacyprior to field studies, includingwhich
effector mechanisms may contribute to protective immunity and
whether these may also be effective against the liver stage.
The concept of inducing multistage protection has been a holy
grail of malaria vaccine design, and many attempts to do this
have been reported. Here, we report that a single antigen can
induce significant protective efficacy at the pre-erythrocytic
and erythrocytic stages of infection and following only two immu-
nizations. This reflects, in part, the unusual ability of this vectored
vaccine regime to induce both high titers of antibody and strong
T cell responses. These data encourage the development of
vaccine technologies that can induce strong antibody and
T cell responses against multistage malaria antigens in order to
achieve maximal protective efficacy.
EXPERIMENTAL PROCEDURES
Generation of Recombinant MVA and AdHu5 Vaccines
The generation of AdHu5 and MVA vectors expressing P. yoelii YM MSP-142
and MSP-142-C4bp has been described (Draper et al., 2008). Those express-
ing P. yoelii YM MSP-133, MSP-119, and P. yoelii 17XL CSP were made in an
identical manner. Specific cloning details can be found in the Supplemental
Data. MSP-133, MSP-119, and CSP were expanded by PCR from template
DNA and cloned into the MVA shuttle vector pMVA.GFP, and recombinant
MVAs were generated as previously described. Recombinant AdHu5 vaccines
were constructed using the ViraPower Adenoviral Expression System (Invitro-
gen) and purified using the Adenopure Kit (PureSyn; Malvern, PA). AdHu5 and
MVA vectors, expressing a synthetic construct consisting of GFP fused at the
N terminus to one HLA class I- and one class II-restricted epitope from influ-
enza virus, were generated in the same manner and used as vector controls
for immunization.
Animals and Immunizations
Female BALB/c (H-2d) mice (Harlan, UK), 6–8weeks old, were used in all exper-
iments. All procedures were carried out under the terms of the UK Animals
(Scientific Procedures) Act Home Office Project License and were approved
by the University of Oxford Animal Care and Ethical Review Committee. Mice
were immunized intradermally (i.d.) with 5 3 107 pfu MVA vaccines or 5 3
1010vpAdHu5vaccinesdiluted inPBSandadministeredbilaterally into theears.
ELISA
Serum was analyzed for antibodies as previously described (Draper et al.,
2008). Recombinant GST fusion proteins (GST-MSP-133 or GST-MSP-119) orCell HGST control were adsorbed to 96-well Nunc-Immuno Maxisorp plates at
a concentration of 2 mg/mL in PBS. Briefly, plates were washed with PBS
containing 0.05% Tween 20 (PBS/T) and blocked with 10% skimmed milk
powder in PBS/T. Sera were diluted to 1:100, added in duplicate wells, and
serially diluted. Bound antibodies were detected using alkaline phospha-
tase-conjugated goat anti-mouse total IgG. Plates were developed by adding
p-nitrophenylphosphate substrate. Optical density was read at 405 nm
(OD405). Endpoint titers were taken as the x axis intercept of the dilution curve
at an absorbance value 33 standard deviations greater than the OD405 for
naive mouse serum (typical cut-off OD405 for positive sera = 0.15). A high-titer
serum sample was included in all assays as a reference control. All GST control
ELISAs were negative (data not shown).
Multiparameter Flow Cytometry
Cytokine secretion by mouse splenocytes was assayed as described
previously (Draper et al., 2008). Briefly, splenocytes were restimulated in the
presence of GolgiPlug (BD Biosciences) for 5 hr at 37C with pools of 15
mer peptides overlapping by 10 amino acids (final concentration: 5 mg/mL
for each peptide). Overlapping peptide pools corresponded to MSP-133 con-
taining 52 peptides or MSP-119 containing 19 peptides. Staining antibodies
were specific for mouse and purchased from eBioscience. After blocking Fc
receptors with anti-CD16/CD32, cells were surface stained for 30 min at 4C
with Pacific Blue-labeled anti-CD8a and APC-Alexa Fluor 750-labeled
anti-CD4. Cells were permeabilized in Cytofix/Cytoperm solution as per manu-
facturer’s instructions (BD Biosciences). Intracellular cytokines were stained
with PE-labeled anti-IFN-g, APC-labeled anti-TNF-a, and FITC-labeled anti-
IL-2. Samples were analyzed using a CyAn ADP Flow Cytometer (Dako; Ely,
UK) and FlowJo version 8.7 (Tree Star, Inc.; USA). The Boolean gate platform
was used with individual cytokine gates to create all possible response combi-
nations. Pestle 1.5 and SPICE 4.1 software programs (Mario Roederer; VRC,
NIAID, NIH) were used to analyze the T cell response profiles. Background
responses in unstimulated control cells were subtracted from the stimulated
response.
In Vivo Depletions
In vivo-depleting monoclonal antibodies (mAbs) were purified by protein
G affinity chromatography from hybridoma culture supernatants. Anti-CD4
GK1.5 (rat IgG2a) and anti-CD8 2.43 (rat IgG2a) were diluted in sterile PBS.
Normal rat IgG (nRatIgG) was purchased from Sigma and purified by the
same method. For depletion of CD4+ or CD8+ T cells, mice were injected
intraperitoneally (i.p.) with 200 mg of the relevant mAb on days 2 and 1
before and on the day of challenge. In vivo T cell depletion was confirmed
by flow cytometry of surface-stained peripheral blood mononuclear cells
(PBMCs) from depleted and control mice. To inhibit macrophages, mice
were administered 1 mg of Carrageenan (CGN) (Sigma) i.p. on days 0, 1,
and 2 relative to challenge on day 0. To deplete NK cells, mice received a single
dose of 200 ml of anti-asialo GM1 antiserum (Alpha Labs, UK) diluted 1:8 in
0.53 PBS on days 2, 0, and +2 relative to challenge.
P. yoelii (Strain YM) Challenge
Mice were challenged with 104 pRBCs by the intravenous (i.v.) route as previ-
ously described (Draper et al., 2008). Blood-stage parasitemia was monitored
from day 2 postchallenge by microscopic examination of Giemsa-stained
blood smears. Levels of parasitemia are calculated as the percentage of
pRBCs. Mice were deemed uninfected in the absence of patent parasitemia
in 50 fields of view. Infection was considered lethal when parasitemia ex-
ceeded 80%, at which point animals were euthanized. For spz challenge,
salivary glands of infected Anopheles stephensi mosquitoes were dissected
and homogenized in RPMI 1640 medium to release parasites. Mice were
challenged i.v. with 50 or 250 sporozoites, and parasitemia was monitored
from day 5.
Quantification of P. yoelii Parasite Burden in the Liver
Specific details can be found in the Supplemental Data. Mice were challenged
with 5000 sporozoites. Livers were harvested after 48 hr and snap frozen in
liquid nitrogen. Whole livers were homogenized in Trizol (Invitrogen), and total
liver RNAwas extracted using chloroform. RNAwas digestedwith RNase-Free
DNase (QIAGEN, UK) and purified. Two micrograms of RNA was reverseost & Microbe 5, 95–105, January 22, 2009 ª2009 Elsevier Inc. 103
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18S rRNA or mouse glyceraldehyde-3-phosphate dehydrogenase (mGAPDH)
was amplified in triplicate by quantitative real-time PCR using a Rotor-Gene
3000 (Corbett Life Science, Australia). Twenty picomoles of specific primer
pairs were included in the QuantiTect RT-PCR Buffer (QIAGEN) containing
the dsDNA-specific fluorescent dye SYBR Green I. The temperature profile
of the reaction was previously described (Bruna-Romero et al., 2001). The
threshold cycle value (CT) of each PCR was converted to a DNA copy number
equivalent by reading against standard curves generated by amplifying 10-fold
dilutions of plasmid containing the relevant target cDNA molecule. The liver-
stage parasite burden was determined for each sample as the ratio of the
DNA copy number equivalent measured for the P. yoelii 18S rRNA over the
DNA equivalent for mGAPDH.
Serum Cytokine Analysis
A Cytometric Bead Array (Mouse Inflammation Kit, CBA; BD Biosciences) was
used to study cytokine levels in mouse serum. Serum was collected from tail
vein bleeds, stored on ice, centrifuged, and frozen prior to analysis. Serum
was diluted 1:2 and analyzed according to manufacturer’s instructions.
Statistical Analysis
Data were analyzed using GraphPad Prism version 4.03 for Windows
(GraphPad Software; San Diego, CA). Data set normality was assessed by
Kolmogorov-Smirnov test. ELISA endpoint titers were normalized by log10
transformation. Independent-samples Student’s t test was performed to
compare mean responses between two groups. One-way between-groups
ANOVA with post hoc Bonferroni or Dunnett’s correction, as appropriate,
was used to compare responses between more than two groups. Survival
analysis was performed using Fisher’s exact test (two-tailed). A value of
p% 0.05 was considered significant in all cases.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and four figures and can be found online at http://www.
cell.com/cellhostandmicrobe/supplemental/S1931-3128(08)00403-4.
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